GLUT1-DS Italian registry: past, present, and future: a useful tool for rare disorders.
GLUT1 deficiency syndrome
Patient registry
Rare disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
21 03 2023
21 03 2023
Historique:
received:
23
06
2022
accepted:
06
02
2023
entrez:
22
3
2023
pubmed:
23
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
GLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases. To describe the implementation of a national web-based registry for GLUT1-DS. This is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient's sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient's demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies. Five Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments. We describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.
Sections du résumé
BACKGROUND
GLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases.
OBJECTIVE
To describe the implementation of a national web-based registry for GLUT1-DS.
METHODS
This is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient's sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient's demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies.
RESULTS
Five Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments.
CONCLUSIONS
We describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.
Identifiants
pubmed: 36944981
doi: 10.1186/s13023-023-02628-2
pii: 10.1186/s13023-023-02628-2
pmc: PMC10029278
doi:
Substances chimiques
Glucose Transporter Type 1
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Informations de copyright
© 2023. The Author(s).
Références
Int J Environ Res Public Health. 2021 Nov 15;18(22):
pubmed: 34831724
Dev Med Child Neurol. 2007 Sep;49(9):707-16
pubmed: 17718830
Epilepsia Open. 2020 Aug 13;5(3):354-365
pubmed: 32913944
JAMA Neurol. 2017 Jun 1;74(6):727-732
pubmed: 28437535
Seizure. 2016 Feb;35:83-7
pubmed: 26803281
Epilepsia. 2012 Dec;53(12):e204-7
pubmed: 23106342
Public Health Genomics. 2016;19(2):108-15
pubmed: 26998603
Epilepsia. 2015 Dec;56(12):e203-8
pubmed: 26537434
Patient Educ Couns. 2016 Dec;99(12):1923-1939
pubmed: 27450481
Curr Neurol Neurosci Rep. 2013 Apr;13(4):342
pubmed: 23443458
Epilepsy Behav. 2014 Oct;39:111-5
pubmed: 25240122
Pharmaceut Med. 2020 Jun;34(3):185-190
pubmed: 32215853
Dev Med Child Neurol. 2011 Jul;53(7):658-63
pubmed: 21501156
Brain Behav. 2019 Mar;9(3):e01224
pubmed: 30714351
J Child Neurol. 2015 Feb;30(2):160-9
pubmed: 24789115
Int J Environ Res Public Health. 2018 Aug 03;15(8):
pubmed: 30081484
Adv Exp Med Biol. 2017;1031:149-164
pubmed: 29214570
Seizure. 2013 Dec;22(10):803-11
pubmed: 23890838
Epilepsia. 2022 Jul;63(7):1748-1760
pubmed: 35441706
Dev Med Child Neurol. 2013 May;55(5):440-7
pubmed: 23448551